Corbus Pharmaceuticals Holdings, Inc. Cash and Restricted Cash
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Cash and Restricted Cash of $23.75 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $23.75M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $26.05M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $29.16M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27.65M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $23.75M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $26.05M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $29.16M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $27.65M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $20.71M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $19.57M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $17.87M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $20.09M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $24.36M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $14.77M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $14.39M 10-K · filed 2025-03-11 | $14.39M 10-K · filed 2024-03-12 |
| 2023-09-30 | $11.92M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $9.02M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $7.99M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $17.67M 10-K · filed 2024-03-12 | |
| 2022-09-30 | $13.11M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $26.44M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $57.70M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $25.68M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $37.79M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $36.75M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $67.63M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $86.45M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $82.89M 10-Q · filed 2020-11-09 | |
| 2019-12-31 | $31.75M 10-K · filed 2021-03-15 | |
| 2019-03-31 | $89.92M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $41.75M 10-Q · filed 2019-05-09 | |
| 2018-09-30 | $55.66M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $64.68M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $70.96M 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $62.70M 10-Q · filed 2019-05-09 | |
| 2017-09-30 | $36.80M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $43.23M 10-Q · filed 2018-08-08 | |
| 2017-03-31 | $49.13M 10-Q · filed 2018-05-10 | |
| 2016-12-31 | $15.19M 10-K · filed 2019-03-12 | |
| 2016-09-30 | $19.10M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $22.06M 10-Q · filed 2017-08-09 | |
| 2015-12-31 | $12.37M 10-K · filed 2018-03-12 | |
| 2014-12-31 | $6.28M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |